TCGA-CV-6950-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.104794521
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.490
- MITOTIC_SPINDLE+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- G2M_CHECKPOINT+0.450
- MYOGENESIS+0.450
- E2F_TARGETS+0.410
- TGF_BETA_SIGNALING+0.400
- HYPOXIA+0.290
- NOTCH_SIGNALING+0.290
- ANGIOGENESIS+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.390
- PANCREAS_BETA_CELLS-0.270
- FATTY_ACID_METABOLISM-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- ALLOGRAFT_REJECTION-0.240
- PEROXISOME-0.230
- BILE_ACID_METABOLISM-0.220
- KRAS_SIGNALING_DN-0.160
- CHOLESTEROL_HOMEOSTASIS-0.150
- PROTEIN_SECRETION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8288-01A-11R-2296-07 | — | cohortSQ1 | 0.787 |
| 2 | TCGA-F7-8298-01A-11R-2403-07 | — | — | 0.779 |
| 3 | SRR27320698 | — | — | 0.778 |
| 4 | SRR5903555 | — | cohortSQ1 | 0.774 |
| 5 | SRR10899983 | — | — | 0.757 |
| 6 | TCGA-CR-7365-01A-11R-2016-07 | — | — | 0.756 |
| 7 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.754 |
| 8 | TCGA-37-A5EM-01A-21R-A27Q-07 | — | cohortSQ1 | 0.753 |
| 9 | e040e6c8-34e5-44fb-a6f3-c247009fccfc | — | — | 0.735 |
| 10 | SRR8518161 | — | E | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYOGENESIS | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |